Wedge Capital Management L L P NC Sells 21,403 Shares of Cencora, Inc. $COR

Wedge Capital Management L L P NC lessened its position in shares of Cencora, Inc. (NYSE:COR) by 19.5% in the third quarter, Holdings Channel reports. The fund owned 88,409 shares of the company’s stock after selling 21,403 shares during the quarter. Wedge Capital Management L L P NC’s holdings in Cencora were worth $27,630,000 as of its most recent filing with the SEC.

Other institutional investors also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC grew its stake in shares of Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares during the period. Caldwell Trust Co purchased a new position in shares of Cencora in the second quarter worth approximately $46,000. Capital A Wealth Management LLC boosted its holdings in shares of Cencora by 3,975.0% in the second quarter. Capital A Wealth Management LLC now owns 163 shares of the company’s stock worth $49,000 after buying an additional 159 shares during the last quarter. Finally, Twin Peaks Wealth Advisors LLC bought a new stake in Cencora during the second quarter valued at approximately $52,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analyst Weigh In

COR has been the topic of several recent research reports. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price target on the stock. TD Cowen upped their price objective on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. Wall Street Zen cut Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Wells Fargo & Company lifted their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. Finally, JPMorgan Chase & Co. lifted their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a research report on Tuesday, November 11th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $373.25.

Insider Activity

In other news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the sale, the chief executive officer directly owned 65,746 shares of the company’s stock, valued at $24,105,113.44. This represents a 7.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 10.80% of the stock is owned by company insiders.

Cencora Stock Up 0.1%

NYSE COR opened at $341.07 on Friday. The stock has a market cap of $66.16 billion, a PE ratio of 42.90, a P/E/G ratio of 1.62 and a beta of 0.63. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $377.54. The stock’s 50 day moving average is $346.49 and its 200 day moving average is $313.16.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $3.34 earnings per share. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 14th were paid a dividend of $0.60 per share. The ex-dividend date of this dividend was Friday, November 14th. This is a boost from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.